General Information of Drug (ID: DMTXCUS)

Drug Name
Galiximab Drug Info
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMTXCUS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Abatacept DMSA8RU Alopecia areata ED70.2 Approved [3]
RhuDex DMGM1IR Rheumatoid arthritis FA20 Phase 2a [4]
HS-110 DML4RCG Non-small-cell lung cancer 2C25.Y Phase 2 [5]
MAXY-4 DMMP7XG Autoimmune diabetes 5A10 Phase 1 [6]
CAR-T cells targeting CD80/86 DM6Z7AD Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
Tolerimab DMZKIE0 Transplant rejection NE84 Terminated [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activation B7-1 antigen (CD80) TTFZDNP CD80_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT00516217) Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma. U.S. National Institutes of Health.
2 Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8.
3 Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8.
4 A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
5 Clinical pipeline report, company report or official report of Heat Biologics.
6 Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3.
7 ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
8 US patent application no. 2004,0171,123, Albumin fusion proteins.